Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137907 | 0.86 | NPC1 (0.62) | NPC1KMT2AALDH1A1RAB9APDCD1 | |
| SCHEMBL21676265 | 0.85 | TSHR (0.53) | USP2NPC1MAPTPOLBCA12 | |
| SCHEMBL5081284 | 0.84 | USP2 (0.62) | USP2NPC1KMT2ACES2CES1 | |
| SCHEMBL11229093 | 0.84 | ALDH1A1 (0.51) | USP2NPC1KMT2ACES2CES1 | |
| SCHEMBL15771342 | 0.82 | NPC1 (0.49) | USP2NPC1KMT2AALDH1A1MAPT | |
| SCHEMBL1253296 | 0.81 | NPC1 (0.48) | USP2NPC1KMT2AALDH1A1MAPT | |
| SCHEMBL10776009 | 0.81 | USP2 (0.52) | USP2NPC1KMT2ACES2CES1 | |
| SCHEMBL29136152 | 0.81 | USP2 (0.59) | USP2NPC1KMT2ACES2CES1 | |
| SCHEMBL21866481 | 0.81 | CES2 (0.52) | USP2NPC1KMT2ACES2CES1 | |
| SCHEMBL22164112 | 0.80 | NPC1 (0.57) | NPC1KMT2AALDH1A1RAB9APDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533941-B2 | Methods of synthesizing a levodopa ester prodrug | XENOPORT, INC. (US) | 2017-01-03 | — | — | US | claimed |
| US-20160176804-A1 | METHODS OF SYNTHESIZING A LEVODOPA ESTER PRODRUG | WILSHIRE PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | claimed |
| US-9290445-B2 | Methods of synthesizing a levodopa ester prodrug | XENOPORT, INC. (US) | 2016-03-22 | — | — | US | claimed |
| CN-101318887-B | Method for preparing indene compounds | SHANGHAI RES INST CHEMICAL IND | 2011-03-23 | — | — | CN | claimed |
| US-20100099907-A1 | Methods of Synthesizing a Levodopa Ester Prodrug | XENOPORT, INC. | 2010-04-22 | — | — | US | claimed |
| CN-101318887-A | Method for preparing indene compounds | SHANGHAI RES INST CHEMICAL IND (CN) | 2008-12-10 | — | — | CN | claimed |
| US-5380910-A | Dehalogeno coupling | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-01-10 | — | — | US | claimed |
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-23 | — | — | US | disclosed |
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-23 | — | — | US | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2020-12-24 | — | — | US | disclosed |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-02-06 | — | — | US | disclosed |
| CN-104828806-B | A graphene modifier, a graphene reinforced composite material and a preparing method of the graphene reinforced composite material | 东莞劲胜精密组件股份有限公司 | 2017-01-11 | — | — | CN | disclosed |
| WO-2000075203-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075202-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075204-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000052068-A1 | PROCESS FOR PRODUCING POLYETHYLENE | EASTMAN CHEMICAL COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0571770-B1 | Method for producing an asymmetric biaryl derivative | IHARA CHEMICAL IND CO (JP) | 1996-07-10 | — | — | EP | disclosed |
| US-5380910-A | Dehalogeno coupling | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0571770-A1 | Method for producing an asymmetric biaryl derivative | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 1993-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | GUSB, NTPCR, FOLH1 | USP2 2008/4885NPC1 856/4885KMT2A 1378/4885 |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | USP2 1231/4885NPC1 4566/4885KMT2A 276/4885 |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | BRD4, BET1, BRD3 | USP2 1160/4885NPC1 4455/4885KMT2A 339/4885 |
| US-20160176804-A1 | METHODS OF SYNTHESIZING A LEVODOPA ESTER PRODRUG | COMT, DDT, MAOB | USP2 2513/4885NPC1 2829/4885KMT2A 1664/4885 |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | GUSB, NTPCR, FOLH1 | USP2 2008/4885NPC1 856/4885KMT2A 1378/4885 |
| US-20100099907-A1 | Methods of Synthesizing a Levodopa Ester Prodrug | COMT, DDT, MAOB | USP2 2513/4885NPC1 2829/4885KMT2A 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.